220 related articles for article (PubMed ID: 35890327)
1. Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder.
Saha T; Sinha S; Harfoot R; Quiñones-Mateu ME; Das SC
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890327
[TBL] [Abstract][Full Text] [Related]
2. Preparation and Characterization of Inhalable Ivermectin Powders as a Potential COVID-19 Therapy.
Albariqi AH; Ke WR; Khanal D; Kalfas S; Tang P; Britton WJ; Drago J; Chan HK
J Aerosol Med Pulm Drug Deliv; 2022 Oct; 35(5):239-251. PubMed ID: 35275749
[No Abstract] [Full Text] [Related]
3. Spray-Dried Inhalable Microparticles Combining Remdesivir and Ebselen against SARS-CoV-2 Infection.
Saha T; Sinha S; Harfoot R; Quiñones-Mateu ME; Das SC
Pharmaceutics; 2023 Aug; 15(9):. PubMed ID: 37765198
[TBL] [Abstract][Full Text] [Related]
4. Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization.
Saha T; Sinha S; Harfoot R; Quiñones-Mateu ME; Das SC
Int J Pharm; 2023 Oct; 645():123411. PubMed ID: 37703955
[TBL] [Abstract][Full Text] [Related]
5. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
[TBL] [Abstract][Full Text] [Related]
6. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections.
Saha T; Lyons N; Yue Yung DB; Quiñones-Mateu ME; Pletzer D; Das SC
Eur J Pharm Biopharm; 2024 Feb; 195():114170. PubMed ID: 38128743
[TBL] [Abstract][Full Text] [Related]
7. Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Doyle C; Das SC
Int J Pharm; 2017 Aug; 528(1-2):107-117. PubMed ID: 28583333
[TBL] [Abstract][Full Text] [Related]
8. Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies.
Momin MAM; Rangnekar B; Sinha S; Cheung CY; Cook GM; Das SC
Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31581469
[TBL] [Abstract][Full Text] [Related]
9. Inhalable co-amorphous budesonide-arginine dry powders prepared by spray drying.
Lu W; Rades T; Rantanen J; Yang M
Int J Pharm; 2019 Jun; 565():1-8. PubMed ID: 30999050
[TBL] [Abstract][Full Text] [Related]
10. Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug.
Momin MAM; Tucker IG; Doyle CS; Denman JA; Das SC
Int J Pharm; 2018 May; 543(1-2):318-327. PubMed ID: 29626509
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
Wang J; Kutter JP; Mu H; Moodley A; Yang M
Int J Pharm; 2020 Nov; 590():119877. PubMed ID: 32927003
[TBL] [Abstract][Full Text] [Related]
12. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
[TBL] [Abstract][Full Text] [Related]
13. Characterization of excipient enhanced growth (EEG) tobramycin dry powder aerosol formulations.
Hassan A; Farkas D; Longest W; Hindle M
Int J Pharm; 2020 Dec; 591():120027. PubMed ID: 33130220
[TBL] [Abstract][Full Text] [Related]
14. Development of excipients free inhalable co-spray-dried tobramycin and diclofenac formulations for cystic fibrosis using two and three fluid nozzles.
Marasini N; Sheikh Z; Wong CYJ; Hosseini M; Spicer PT; Young P; Xin Ong H; Traini D
Int J Pharm; 2022 Aug; 624():121989. PubMed ID: 35809834
[TBL] [Abstract][Full Text] [Related]
15. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
Son YJ; Worth Longest P; Hindle M
Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
[TBL] [Abstract][Full Text] [Related]
16. Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.
Shetty N; Park H; Zemlyanov D; Mangal S; Bhujbal S; Zhou QT
Int J Pharm; 2018 Jun; 544(1):222-234. PubMed ID: 29678544
[TBL] [Abstract][Full Text] [Related]
17. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection.
Arora S; Haghi M; Loo CY; Traini D; Young PM; Jain S
Mol Pharm; 2015 Jun; 12(6):2001-9. PubMed ID: 25923171
[TBL] [Abstract][Full Text] [Related]
18. Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis.
Fan C; Eedara BB; Sinha S; Uddin MKM; Doyle C; Banu S; Das SC
Int J Pharm; 2024 Apr; 654():123984. PubMed ID: 38461874
[TBL] [Abstract][Full Text] [Related]
19. Engineering of levodopa inhalable microparticles in combination with leucine and dipalmitoylphosphatidylcholine by spray drying technique.
Bahrainian S; Mirmoeini MS; Gilani Z; Gilani K
Eur J Pharm Sci; 2021 Dec; 167():106008. PubMed ID: 34530077
[TBL] [Abstract][Full Text] [Related]
20. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections.
Momin MAM; Tucker IG; Doyle CS; Denman JA; Sinha S; Das SC
Int J Pharm; 2018 Apr; 541(1-2):26-36. PubMed ID: 29458207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
